<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079971</url>
  </required_header>
  <id_info>
    <org_study_id>A 096043</org_study_id>
    <nct_id>NCT05079971</nct_id>
  </id_info>
  <brief_title>EAGLET: EEG vs aEEG to Improve the Diagnosis of neonataL Seizures and Epilepsy</brief_title>
  <acronym>EAGLET</acronym>
  <official_title>The EAGLET Project: EEG vs aEEG to Improve the Diagnosis of neonataL Seizures and Epilepsy - a Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norfolk and Norwich University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Luton and Dunstable Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Infant, University College Cork, Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Evelina Hospital, London, Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current project undertakes a prospective multicentre randomised controlled trial to&#xD;
      evaluate whether full or continuous electroencephalography (cEEG) is superior to&#xD;
      amplitude-integrated electroencephalography (aEEG) in the real time evaluation and diagnosis&#xD;
      of neonatal seizures and in reducing time to treatment. At-risk new-born infants will be&#xD;
      recruited on the participating neonatal intensive care units (NICUs) by trained specialist&#xD;
      staff and will have 24 hours of EEG monitoring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Seizures are the most common neurological emergency in the neonatal period, affecting over&#xD;
      2000 infants per year in the UK. Although neonatal seizures usually result from acute brain&#xD;
      insults, about 10-15% represent genetic forms of epilepsy which are often diagnosed late,&#xD;
      thus limiting the timely use of targeted therapies. Lack or delayed initiation of treatment&#xD;
      results in a high seizure burden which is independently associated with worse clinical&#xD;
      outcomes.&#xD;
&#xD;
      Diagnosing neonatal seizures is challenging because most have only subtle or no clinical&#xD;
      manifestation. The gold standard for seizure detection is continuous electroencephalography&#xD;
      (cEEG). cEEG can assist with establish the aetiology of seizures, and their management.&#xD;
      However, this capability is lacking in most neonatal intensive care units (NICU) due to lack&#xD;
      of on-site specialist support. The more common amplitude-integrated EEG (aEEG) uses a limited&#xD;
      number of electrodes and is easier to apply and interpret but has been shown to miss a&#xD;
      significant number of seizures. It is unclear how often seizure treatment is missed or&#xD;
      delayed due to lack of cEEG access. Although studies have compared the diagnostic value of&#xD;
      aEEG and cEEG retrospectively, the measured sensitivity of aEEG ranges widely (25-85%),&#xD;
      likely due to poor design (retrospective, lack of adequate control group, no power&#xD;
      calculations).&#xD;
&#xD;
      The current project undertakes a prospective multicentre randomised controlled trial to&#xD;
      evaluate whether cEEG is superior to aEEG in the real time evaluation and diagnosis of&#xD;
      neonatal seizures and in reducing time to treatment. At-risk neonates will be recruited on&#xD;
      the NICU by trained specialist staff and will have 24 hours of EEG monitoring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizure detection yield of aEEG compared to full EEG</measure>
    <time_frame>Each participant will be assessed in Group A (aEEG review only) or Group B (a+cEEG) for 24 hours.</time_frame>
    <description>The primary outcome measure for the study is the difference in the number of correctly identified seizures by NICU staff in real time with (full EEG) or without (aEEG only) the support of clinical neurophysiology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from first recorded seizure to first recognised seizure and to treatment.</measure>
    <time_frame>Each participant's seizure burden, treatment and discharge timelines will be recorded up until their discharge from the hospital, or for up to 6 months, whichever came first.</time_frame>
    <description>Their time to treatment and time to discharge will also be noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of false positive seizure detections clinically and/or by aEEG</measure>
    <time_frame>Followed until their discharge from hospital, or for up to 6 months, whichever came first.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Off-line seizure burden (min/hr) detected by aEEG vs detected by cEEG</measure>
    <time_frame>Followed until their discharge from hospital, or for up to 6 months, whichever came first.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parental and staff acceptance of EEG monitoring (combined cohort) using questionnaire.</measure>
    <time_frame>Parents may fill in the questionnaire online after their infant's discharge from hospital, the questionnaire will take a maximum of 10 minutes to complete.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Neonatal Seizures</condition>
  <arm_group>
    <arm_group_label>Group A is a control group with aEEG monitoring only, and with retrospective cEEG review</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B is undergoing aEEG monitoring with concurrent full EEG review</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Group B: aEEG with concurrent multichannel (full) continuous cEEG review by clinical neurophysiology</intervention_name>
    <description>In group B, the standart-care equivalent aEEG review is undertaken by NICU staff via a 2-channel display. In addition to the standard care, concurrent full EEG is reviewed remotely with regular feedback by a specialist trained clinical neurophysiologist. The clinical neurophysiology reports only on seizure burden, no information or direction is provided regarding clinical management.</description>
    <arm_group_label>Group A is a control group with aEEG monitoring only, and with retrospective cEEG review</arm_group_label>
    <arm_group_label>Group B is undergoing aEEG monitoring with concurrent full EEG review</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Term or preterm neonate, born at post-menstrual age (PMA) 32-44 weeks;&#xD;
&#xD;
          2. And at least one of the following:&#xD;
&#xD;
             (2.1) Neonate with any clinical event suspicious of seizures (2.2) Neonate at&#xD;
             high-risk of seizures with confirmed or suspected: (2.2.1) Hypoxic ischaemic&#xD;
             encephalopathy (moderate to severe, or deemed eligible for therapeutic hypothermia)&#xD;
             (2.2.2) Cerebral vascular insult (e.g., perinatal arterial ischaemic stroke, cerebral&#xD;
             venous sinus thrombus) (2.2.3) Meningitis / encephalitis - Inflammatory (2.2.4) Inborn&#xD;
             error of metabolism (2.2.5) Brain malformation (2.2.6) Large intraventricular&#xD;
             haemorrhage (III-IV)&#xD;
&#xD;
          3. Infant is up to 28 days of age&#xD;
&#xD;
          4. Written informed parental consent can be obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No parental consent&#xD;
&#xD;
          2. Poor prognosis of immediate survival&#xD;
&#xD;
          3. Any contraindication to perform EEG (e.g. structural pathologies interfering with EEG&#xD;
             electrode placement, such as cephalohematoma or subgaleal haemorrhage).&#xD;
&#xD;
          4. Infants born at less than 31+6 weeks PMA and infants who are or are suspected to be&#xD;
             experiencing or are at high-risk of seizures when aged 29 days or older.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>32 Weeks</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ronit M Pressler, MD, CCT, Phd, MRCPCH</last_name>
    <phone>07737333607</phone>
    <phone_ext>+44</phone_ext>
    <email>r.pressler@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Topun Austin, MD MBBS MRCP(Paeds) MRCPCH PhD</last_name>
    <phone>01223217677</phone>
    <phone_ext>+44</phone_ext>
    <email>topun.austin@addenbrookes.nhs.uk</email>
  </overall_contact_backup>
  <reference>
    <citation>Pinchefsky EF, Hahn CD. Outcomes following electrographic seizures and electrographic status epilepticus in the pediatric and neonatal ICUs. Curr Opin Neurol. 2017 Apr;30(2):156-164. doi: 10.1097/WCO.0000000000000425. Review.</citation>
    <PMID>28118303</PMID>
  </reference>
  <reference>
    <citation>Malone A, Ryan CA, Fitzgerald A, Burgoyne L, Connolly S, Boylan GB. Interobserver agreement in neonatal seizure identification. Epilepsia. 2009 Sep;50(9):2097-101. doi: 10.1111/j.1528-1167.2009.02132.x. Epub 2009 Jun 1.</citation>
    <PMID>19490044</PMID>
  </reference>
  <reference>
    <citation>Boylan GB, Kharoshankaya L, Mathieson SR. Diagnosis of seizures and encephalopathy using conventional EEG and amplitude integrated EEG. Handb Clin Neurol. 2019;162:363-400. doi: 10.1016/B978-0-444-64029-1.00018-7. Review.</citation>
    <PMID>31324321</PMID>
  </reference>
  <reference>
    <citation>Pellegrin S, Munoz FM, Padula M, Heath PT, Meller L, Top K, Wilmshurst J, Wiznitzer M, Das MK, Hahn CD, Kucuku M, Oleske J, Vinayan KP, Yozawitz E, Aneja S, Bhat N, Boylan G, Sesay S, Shrestha A, Soul JS, Tagbo B, Joshi J, Soe A, Maltezou HC, Gidudu J, Kochhar S, Pressler RM; Brighton Collaboration Neonatal Seizures Working Group. Neonatal seizures: Case definition &amp; guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2019 Dec 10;37(52):7596-7609. doi: 10.1016/j.vaccine.2019.05.031. Review.</citation>
    <PMID>31783981</PMID>
  </reference>
  <reference>
    <citation>Gossling L, Alix JJP, Stavroulakis T, Hart AR. Investigating and managing neonatal seizures in the UK: an explanatory sequential mixed methods approach. BMC Pediatr. 2020 Jan 28;20(1):36. doi: 10.1186/s12887-020-1918-4.</citation>
    <PMID>31992265</PMID>
  </reference>
  <reference>
    <citation>Rakshasbhuvankar A, Paul S, Nagarajan L, Ghosh S, Rao S. Amplitude-integrated EEG for detection of neonatal seizures: a systematic review. Seizure. 2015 Dec;33:90-8. doi: 10.1016/j.seizure.2015.09.014. Epub 2015 Sep 26. Review.</citation>
    <PMID>26456517</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Ronit Pressler</investigator_full_name>
    <investigator_title>Dr (Clinical Neurophysiology)</investigator_title>
  </responsible_party>
  <keyword>Neonatal Seizures</keyword>
  <keyword>cEEG</keyword>
  <keyword>aEEG</keyword>
  <keyword>Epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

